Journal Article

A phase 1b study of the nanoparticle-drug conjugate (NDC) CRLX101 in combination with weekly paclitaxel in patients (pts) with platinum-resistant ovarian cancer (OC)

C.N. Krasner, R.J. Schilder, W.E. Brady, L.R. Duska, D. O'Malley, P.A. Disilvestro, J. Li, W. Downing and A. Senderowicz

in Annals of Oncology

Published on behalf of European Society for Medical Oncology

Volume 27, issue suppl_6 Published in print October 2016 | ISSN: 0923-7534
Published online October 2016 | e-ISSN: 1569-8041 | DOI: http://dx.doi.org/10.1093/annonc/mdw374.11
A phase 1b study of the nanoparticle-drug conjugate (NDC) CRLX101 in combination with weekly paclitaxel in patients (pts) with platinum-resistant ovarian cancer (OC)

Show Summary Details

Journal Article.  420 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.